The CDO of Fate Therapeutics is Exercising Options

By Carrie Williams

Today, the CDO of Fate Therapeutics, ABBOT STEWART, exercised options of Fate Therapeutics for $139.4K.

Following this transaction ABBOT STEWART’s holding in the company was increased by 81.84% to a total of $629K.

See today’s analyst top recommended stocks >>

Currently, Fate Therapeutics has an average volume of 441.4K. The Company has a Price to Book ratio of 8.2794.

Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $17.80, reflecting a -42.8% downside. 10 different firms, including BMO Capital and Cowen & Co., currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.